Abstract 417P
Background
Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. Limited knowledge exists on the expression and clinical meaning of miR-21 in extracellular vesicles (EVs) of breast cancer (BC) patients. Thus, the aim of this study has been to assess EV-derived miR-21 expression in different BC subsets.
Methods
One hundred women were enrolled: 30 with early BC, 30 with metastatic BC on treatment progression, 30 cancer survivors on follow up and 10 healthy controls matched for age and BMI. EVs, isolated from serum samples, were characterized by nanoparticle tracking analyzer (NTA), scanning electron microscopy (SEM) and atomic force microscopy (AFM) to detect their concentration, size and structure. The miR-21 in EVs was evaluated by Real Time PCR. The expression of miR-21 was compared between groups by calculating the ΔΔCt statistic and the fold change, considering miR-16 as the housekeeping gene. The ΔΔCt was calculated using a linear mixed model approach with gene x group interaction as the parameter of interest, adjusting for age, BMI and menopausal status, and considering random intercept and random slope terms to account for individual variability.
Results
No differences in EVs size and concentration among the four groups were detected. Considering the early BC group, the clinical stage at diagnosis and tumor subtype did not influence miR-21 expression. Higher expression of miR-21 has been found in metastatic versus healthy controls (p= 0.029 95% CI -1.549 to -0.079), mainly in HER2+ and hormone receptor positive patients (p 0.0005 and 0.036, respectively). In particular, in HER2+ miR-21 was significantly higher in patients with active BC (early and metastatic) (p 0.002 95% CI -1,707 to -0,376) compared to control group.
Conclusions
While further investigations shall be requested, our data on serum EV suggest that miR-21 may become a promising biomarker for early diagnosis and tumor activity, mainly in HER2+ BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Claudia Omarini.
Funding
MIUR Dipartimenti Eccellenti 2022.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
436TiP - DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
Presenter: Joyce O'Shaughnessy
Session: Poster session 15
437TiP - An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
Presenter: Mridula George
Session: Poster session 15
439TiP - AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
Presenter: Afshin Dowlati
Session: Poster session 15
517P - Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study
Presenter: Aziz Zaanan
Session: Poster session 15
520P - Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
Presenter: Rocio Garcia-Carbonero
Session: Poster session 15
521P - XELOX +bev +tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
Presenter: Kai Ou
Session: Poster session 15